New report recommends continuing collaborations across the life sciences sector
News
EU approves Tukysa combo for advanced HER2-positive breast cancer
In the HER2CLIMB trial, Tukysa-treated patients had a 46% reduction in the risk of cancer progression or death
Evox raises £69.2m to advance exosome-based therapeutics pipeline
Series C financing will also be used for the development of Evox’s DeliverEX exosome drug platform
UK government pledges £18.5m for long COVID research
Funding will be given to four long COVID research studies
Overuse of reliever medication for asthma a ‘major contributor’ to greenhouse gas emissions
New data shows overuse of SABA relievers is responsible for 250,000 tonnes of CO2 emissions annually
Evgen Pharma recruits over 100 patients into COVID-19 trial
Study is investigating company’s lead asset SFX-01
Novartis’ heart failure med Entresto scores an expanded approval in the US
Extended indication in chronic heart failure authorised by the FDA
‘Urgent action needed’ as NHS faces growing waiting lists
A growing number of patients are waiting 52 weeks or more for hospital treatment
EU authorises Celltrion’s adalimumab biosimilar Yuflyma
Yuflyma is approved across 13 indications for the treatment of multiple chronic inflammatory diseases
MHRA launches public consultation on reclassification of two contraceptive pills
Regulatory agency is asking for opinions on reclassifying the pills as pharmacy medications
LifeArc provides £5m funding for COVID-19 genomics study
Study is aiming to understand the role of genetic risk factors in patient responses to COVID-19
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Kidney Research UK pledges support to Accelerate@Babraham initiative
Accelerate@Babraham supports early-stage life sciences ventures within the Babraham Research Campus’ community
NICE rejects Lilly’s Verzenios for advanced breast cancer
CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
CureVac’s COVID-19 vaccine begins rolling review with EMA
CureVac’s CVnCoV is currently being investigated in a randomised, placebo-controlled Phase IIb/III clinical trial
